Applied Therapeutics, Inc. announced successful completion of a recent pre-New Drug Application (?NDA?) meeting with the Food and Drug Administration (FDA) regarding its govorestat (AT-007) Galactosemia program. Based on discussions with the FDA, the Company believes they are aligned with the FDA and plans to submit an NDA for govorestat (AT-007) for the treatment of Galactosemia in the fourth quarter of this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.28 USD | -0.23% | +4.90% | +27.76% |
May. 09 | Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.76% | 489M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.14% | 22.48B | |
-9.70% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- APLT Stock
- News Applied Therapeutics, Inc.
- Applied Therapeutics, Inc. Announces Successful Pre-Nda Meeting with the Fda and Confirms Plans to Submit Nda for Govorestat (At-007) for Treatment of Classic Galactosemia to Fda in Fourth Quarter 2023